UnitedHealthcare Community Plan PDL Modifications

Size: px
Start display at page:

Download "UnitedHealthcare Community Plan PDL Modifications"

Transcription

1 Lialda Mesalamine Apriso Mesalamine Afinitor Disperz Everolimus treatment of ulcerative colitis. treatment of ulcerative colitis. treatment of subependymal giant cell astrocytoma (SEGA) with tuberous sclerosis complect (TSC). Prior Bosulif Bosutinib chronic phase, accelerated phase, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy. Prior authorization required. Available through Iclusig Ponatinib chronic phase, accelerated phase, or blast phase chronic myelogenous leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy and for the treatment of Philadelphia chromosome-positive acute lymphocytic leukemia (ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. Prior Available through Cometriq Cabozantinib progressive, metastatic medullary thyroid cancer. Prior Stivarga Regorafenib metastatic colorectal cancer in patients who have previously received fluoropyrimidine, oxaliplatin, and irinotecan based chemotherapy; an anti-vegf therapy; and an anti-egfr therapy if KRAS wild type. Also for the treatment of locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST) in patients who have previously received imatinib and sunitinib. Prior Cystaran solution 0.44% Gattex Cysteamine Teduglutide corneal cysteine crystal accumulation in patients with cystinosis. Prior Available through short bowel syndrome in patients who are dependent on parenteral support. Prior Juxtapid Lomitapide homozygous familial hypercholesterolemia (HoFH). Prior Available through * Only Generics are covered Page 1 of 5

2 Marinol* Aubagio Gilenya Dronabinol* Teriflunomide Fingolimod chemotherapy-induced nausea/vomiting (CINV) that is refractory to conventional antiemetic agents and for use as an appetite stimulant in patients with anorexia due to AIDS. Prior authorization required. relapsing forms of multiple sclerosis. Prior relapsing forms of multiple sclerosis. Prior Eliquis Apixaban Added as an alternative agent for stroke prophylaxis and systemic embolism prophylaxis in patients with nonvalvular atrial fibrillation. Prior Norditropin Somatropin Ritalin LA* Methylphenidate ER* Eli Lilly Insulin Vials: Humalog Insulin Lispro Humilin R Insulin Regluar Humulin N Insulin Isophane Humulin 70/30 Insulin Isophane/Regular Humalog Mix 75/25 Insulin Lispro Prot/Lispro Humalog Mix 50/50 Insulin Lispro Prot/Lispro AccuNeb 0.63 mg/3 ml and Albuterol 0.63 mg/3 ml and 1.25 mg/3 ml* 1.25 mg/3 ml* Omnitrope Cimzia Somatropin Certolizumab pegol 3/1/2013 4/1/2013 Isentress Chewable Raltegravir chewable tablet 3/1/2013 4/1/2013 Lyrica Solution Pregabalin oral solution treatment of growth failure due to growth hormone deficiency. Prior Available through treatment of attention-deficit hyperactivity disorder (ADHD). Added as alternative insulin formulations for the treatment of type 1 and type 2 diabetes mellitus. Added as alternative dosing formulations for the treatment of acute bronchospasm (eg, asthma) and bronchospasm prophylaxis. Age edit applies for members 8 years of age or older. Prior authorization is required for members 8 years of age or older. Alternative formulations are available on the PDL including Tev-Tropin and Norditropin. Current users will not be grandfathered. including Enbrel and Humira. Current users will not be grandfathered. treatment of HIV infection in combination with other antiretroviral agents. Added as alternative dosing formulation to for the treatment of diabetic neuropathy, fibromyalgia, partial seizures, postherpetic neuralgia, and pain associated with spinal cord injury. Prior Added as an alternative agent for the treatment metastatic castration-resistant prostate cancer in patients who have received prior chemotherapy containing docetaxel. Prior 3/1/2013 4/1/2013 Xtandi Enzalutamide Available through Cobicistat/elvitegravir/ 3/1/2013 4/1/2013 Stribild emtricitabine/tenofovir HIV infection in antiretroviral naïve adults. * Only Generics are covered Page 2 of 5

3 3/1/2013 4/1/2013 Entocort Budesonide 3/1/2013 4/1/2013 Rectiv Nitroglycerin rectal ointment 3/1/2013 4/1/2013 Adderall* Amphet/d-amphet salts Modification 3/1/2013 4/1/2013 Adderall XR Amphet/d-amphet salts XR Modification 3/1/2013 4/1/2013 Strattera Atomoxetine Modification 3/1/2013 4/1/2013 Dexedrine* Dextroamphetamine Modification 3/1/2013 4/1/2013 Dextrostat* Dextroamphetamine Modification 3/1/2013 4/1/2013 Dexedrine Spansule* Dextroamphetamine ER Modification 3/1/2013 4/1/2013 Intuniv Guanfacine Modification 3/1/2013 4/1/2013 Ritalin* Methylphenidate Modification 3/1/2013 4/1/2013 Concerta* Methylphenidate ER Modification 3/1/2013 4/1/2013 Metadate ER* Methylphenidate SR Modification 3/1/2013 4/1/2013 Ritalin SR* Methylphenidate SR Modification 3/1/2013 4/1/2013 Vyvanse Lisdexamfetamine Modification 3/1/2013 4/1/2013 Adcirca Tadalafil 3/1/2013 4/1/2013 Pristiq Desvenlafaxine Hecoria* Tacrolimus Combivent Respimat Detrol* Sanctura* Ipratropium/albuterol inhaler Tolterodine Trospium Crohn s disease. Prior pain associated with anal fissures. Prior Maximum age edit changed to 18 years of age. Prior authorization is required for patients 18 years of age and older. Age edit modification only applies to new starts. Current users will be grandfathered. *Only Generics are covered including sildenafil citrate 20 mg tablet, Letairis, and Tracleer. Current users will be grandfathered. including venlafaxine, venlafaxine ER capsules, fluoxetine, sertraline, paroxetine, and citalopram. Current users will be grandfathered. Added as alternative formulation for the treatment of heart, kidney, and liver transplant rejection prophylaxis. Added as alternative formulation to for the treatment of chronic obstructive pulmonary disease (COPD). an overactive bladder with symptoms of urinary frequency, urinary urgency, or urge-related urinary incontinence. Step therapy applies. an overactive bladder with symptoms of urinary frequency, urinary urgency, or urge-related urinary incontinence. Step therapy applies. Orap Duoneb* Plan B One Step* Lifescan (OneTouch, Basic, Profile, SureStep, Ultra ) Test Strips Pimozide Ipratropium/albuterol solution for inhalation Levonorgestrel 1.5 mg tab Tourette s Syndrome. Added as alternative formulation to for the treatment of chronic obstructive pulmonary disease (COPD). Added as an alternative dosing formulation for postcoital contraception. Added as alternative blood glucose testing strips. Effexor XR capsules* Venlafaxine ER capsules Modification Step therapy removed. Enablex Darifenacin including oxybutynin, oxybutynin ER, tolterodine, and trospium. Current users will not be grandfathered. Prescribers and members to be notified Notification to the prescriber will include Vesicare Solifenacin including oxybutynin, oxybutynin ER, tolterodine, and trospium. Current users will not be grandfathered Prescribers and members to be Peg-Intron Peginterferon alfa-2b including Pegasys (peginterferon alfa-2a). Current users will be able to complete their current regimens. * Only Generics are covered Page 3 of 5

4 Bayer (BREEZE 2, CONTOUR and ASCENSIA ) Test Strips Avonex Pen Korlym Pulmicort Inhaler Symbicort Cimzia Forteo Ranexa Penlac Solution 8%* Desenex Powder 2%* Aclovate Cream and Ointment 0.05%* Temovate Gel and Cream 0.5%* Derma-Smooth Oil/FS* Locoid Solution, Cream, and Ointment 0.1%* Dermatop Cream and Ointment 0.1%* Bleph 10 Ophthalmic Ointment* Optipranolol Ophthalmic Sol 0.3%* Dexasol Ophthalmic Sol 0.1%* Interferon beta-1a Mifepristone Budesonide inhalation Budesonide/formoterol Certolizumab pegol Teriparatide Ranolazine Ciclopirox Miconazole topical powder Alclometasone topical cream Clobetasol topical gel and cream Fluocinolone acetonide topical oil Hydrocortisone butyrate topical solution, cream, and ointment Prednicarbate topical cream Sulfacetamide Sodium 10% Metipranolol Ophthalmic Dexamethasone sodium phosphate Alternative diabetic blood glucose testing strips are available on the PDL including Roche (Accu- Chek Aviva, Aviva Plus, Active, Comfort Curve, Compact, SmartView) and Lifescan (OneTouch Basic, Profile, SureStep, Ultra, Verio ) test strips. Current users will not be grandfathered. Prescribers and members to be notified. Notification to the prescriber will include information regarding what to do in order to have member maintained on this medication. treatment of multiple sclerosis. Prior authorization required. Available through Added as alternative agent to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Prior authorization required. Available through Added as an alternative agent for the maintenance treatment of asthma. Added as an alternative agent for the maintenance treatment of asthma. Step therapy applies. Added as an alternative agent for the treatment rheumatoid arthritis and Crohn s disease. Prior specialty pharmacy. osteoporosis. Prior Available through chronic angina. Step therapy applies. Added as an alternative agent for treatment of mild to moderate onychomycosis of fingernails and toenails. treatment of tinea pedis, tinea corporis, tinea cruris, and tinea versicolor. atopic dermatitis. treatment conjunctivitis, corneal ulcer and other superficial infections. Added as an alternative agent for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. treatment of allergic conjunctivitis and allergic marginal corneal ulcer. * Only Generics are covered Page 4 of 5

5 FML Forte Opthalmic Sus Fluorometholone 0.25%* Vasoclear Ophthalmic Sol Naphazoline HCl 0.02%* Clear Eyes Redness Relief* Naphazoline-Glycerin Vasoclear A Ophthalmic Naphazoline/Zinc sulfate Sol* Visine-AC Ophthalmic Sol* Tetrahydrozoline/Zinc sulfate Muro 128 Ophthalmic Sol 5%* Victrelis Cyclocort 0.1% Cream Lokara Lotion 0.5% Topicort Cream and Gel 0.05%* Topicort Cream and Ointment 0.25%* Apexicon Cream and Ointment 0.05%* Westcort Ointment 0.2%* Betoptic-S Ophthalmic Susp 0.25%* Azopt Opthalmic Susp 1%* Sodium chloride hypertonic Boceprevir Amcinonide topical cream Desonide topical lotion Desoximetasone topical cream and gel Desoximetasone topical cream Diflorasone topical cream Hydrocortisone valerate topical ointment Betaxolol HCl Brinzolamide treatment of allergic conjunctivitis, ocular burns or trauma due to corneal injury, thermal or penetration trauma, giant papillary conjunctivitis (GPC), keratitis, postoperative ocular inflammation, vernal keratoconjunctivitis, and chronic anterior uveitis. Added as an alternative agent for the relief of redness of the eye due to minor irritations or relief of burning and irritation due to dryness of the eye or discomfort due to minor irritations. relief of corneal edema. An alternative agent is available on the PDL including Incivek. Current users will be grandfathered. including desonide ointment and cream, alclometasone, fluocinolone, hydrocortisone, and triamcinolone. including betamethasone, fluocinolone, fluticasone cream, hydrocortisone acetate, hydrocortisone butyrate, including timolol, levobunolol, carteolol, and metipranolol. including dorzolamide and dorzolamide/timolol. * Only Generics are covered Page 5 of 5

UnitedHealthcare Community Plan PDL Modifications

UnitedHealthcare Community Plan PDL Modifications Lialda Mesalamine Apriso Mesalamine treatment of ulcerative colitis. treatment of ulcerative colitis. Afinitor Disperz Everolimus treatment of subependymal giant cell astrocytoma (SEGA) with tuberous sclerosis

More information

UnitedHealthcare Community Plan PDL Modifications

UnitedHealthcare Community Plan PDL Modifications 12/1/2013 1/1/2014 Mekinist Trametinib 12/1/2013 1/1/2014 Tafinlar Dabrafenib 12/1/2013 1/1/2014 Tudorza Pressair Aclidinium inhalation 12/1/2013 1/1/2014 Cystagon Cysteamine bitartrate 12/1/2013 1/1/2014

More information

UnitedHealthcare Community Plan PDL Modifications. Added as an alternative agent for the 9/1/ /1/2012

UnitedHealthcare Community Plan PDL Modifications. Added as an alternative agent for the 9/1/ /1/2012 Avonex Pen Interferon beta-1a Added as alternative dosing formulation for the treatment of multiple sclerosis. Prior Korlym Mifepristone Added as alternative agent to control hyperglycemia secondary to

More information

Step Therapy Medications

Step Therapy Medications Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on

More information

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

2015 Step Therapy Prior Authorization Medical Necessity Guidelines Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154

More information

Drug Formulary Update, January 2013

Drug Formulary Update, January 2013 Drug Formulary Update, January 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota

More information

2018 Step Therapy (ST) Criteria

2018 Step Therapy (ST) Criteria 2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

Drug Formulary Update, April 2013

Drug Formulary Update, April 2013 Drug Formulary Update, April 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota

More information

Prescription benefit updates Large group

Prescription benefit updates Large group Prescription benefit updates Large group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe effective medication treatments. The program also helps you save money

More information

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions Alameda Alliance for Health FORMULARY UPDATE Effective: October 27, 2017. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee

More information

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Comparison of representative topical corticosteroid preparations (classified according to the US system) Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),

More information

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics

More information

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL* Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

More information

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 9 Last Review Date: June 22, 2018 Afinitor Description Afinitor and

More information

Aetna Better Health of Illinois Medicaid Formulary Updates

Aetna Better Health of Illinois Medicaid Formulary Updates October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary

More information

ALLERGIC RHINITIS-NASAL

ALLERGIC RHINITIS-NASAL ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE January 22, 2013 SUBJECT EFFECTIVE DATE January 15, 2013 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Drug List (PDL) Update January 15, 2013 Pharmacy Services Vincent D. Gordon, Deputy

More information

Pharmacy Policy Updates-Medicare Advantage

Pharmacy Policy Updates-Medicare Advantage Pharmacy Policy Updates-Medicare Advantage The following recommendations included on this update have been approved by the Pharmacy and Therapeutics Committee. Please note: For Medicare Advantage plans

More information

Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria

Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time

More information

TennCare Program TN MAC Price Change List As of: 03/30/2017

TennCare Program TN MAC Price Change List As of: 03/30/2017 1 TN List Run : 03/30/17 Old PRAZOSIN HCL 5 MG CAPSULE ORAL 03/29/2017 1.11209 1.12560 ( 1.2) CAPTOPRIL 12.5 MG TABLET ORAL 07/07/2015 1.07191 1.10416 ( 2.9) ISOSORBIDE DINITRATE 5 MG TABLET ORAL 03/29/2017

More information

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018

More information

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions Alameda Alliance for Health FORMULARY UPDATE Effective: February 15, 2018. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee

More information

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32

More information

Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria

Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least

More information

TABLE OF CONTENTS (Click on a link below to view the section.)

TABLE OF CONTENTS (Click on a link below to view the section.) Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)

More information

ADHD Medications Table

ADHD Medications Table Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common

More information

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC) INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193

More information

BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES

BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.

More information

NB Drug Plans Formulary Update

NB Drug Plans Formulary Update Bulletin # 963 December 15, 2017 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective December 15, 2017. Included in this bulletin: Special Authorization Benefit

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017

More information

Alprazolam 0.25mg, 0.5mg, 1mg tablets

Alprazolam 0.25mg, 0.5mg, 1mg tablets Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service

More information

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review

More information

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires

More information

ANTICONVULSANT STEP THERAPY

ANTICONVULSANT STEP THERAPY 2019 First Choice VIP Care Plus Formulary Document: 2019 Step Therapy Formulary ID: 19391 Last Updated: 2/2019 Effective Date: 03-01-2019 ANTICONVULSANT STEP THERAPY APTIOM 200 MG APTIOM 400 MG APTIOM

More information

NB Drug Plans Formulary Update

NB Drug Plans Formulary Update Bulletin # 914 October 14, 2015 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective October 14, 2015. Included in this bulletin: Special Authorization Benefit

More information

Effective for all members on August 1, 2017

Effective for all members on August 1, 2017 August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List

More information

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY Coverage Guideline Policy & Procedure HIM.PA.32 Long acting stimulants (Adderall XR, Dexedrine, Metadate CD, Ritalin

More information

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting

More information

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17

More information

PEI Drug Programs. Issue February 20, 2009

PEI Drug Programs. Issue February 20, 2009 PEI Drug Programs Formulary Update Issue 09-01 February 20, 2009 New medications for the treatment of cancer, chronic obstructive pulmonary disease (COPD), osteoporosis, and HIV/AIDS have been approved

More information

Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)

Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals) This report highlights all changes (additions, deletions and removals) to the CVS Caremark Prescribing Guide Standard Control. ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Estring (estradiol)

More information

Mifegymiso. New Exception Status Benefits

Mifegymiso. New Exception Status Benefits OCTOBER 2017 Nova Scotia Formulary Updates Mifegymiso New Exception Status Benefits Prozac (fluoxetine syr) Neupro (rotigotine) Brenzys (etanercept) Changes in Benefit Status Criteria Updates OAB Medications

More information

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17

More information

TABLE OF CONTENTS (Click on a link below to view the section.)

TABLE OF CONTENTS (Click on a link below to view the section.) Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral

More information

2017 Formulary Changes Year to Date

2017 Formulary Changes Year to Date 2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or

More information

July 2017 P&T Updates

July 2017 P&T Updates July 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives ALUNBRIG 3 2 DUPIXENT Pharmacy 3 2 6 tablets per day, 30 day One-week auth for QL of 3 syringes per

More information

Advanced Control Formulary Change Summary Report Effective

Advanced Control Formulary Change Summary Report Effective This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Cystagon (cysteamine bitartrate)

More information

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice MEDICAID PROVIDER BULLETIN October 2018 The formulary changes listed in the table below were reviewed and approved at the second-quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG

More information

Pharmacy and Therapeutics (P&T) Committee Meeting February 16, :00 PM 8:00 PM MINUTES

Pharmacy and Therapeutics (P&T) Committee Meeting February 16, :00 PM 8:00 PM MINUTES P&T Committee Members Matthew Flynn, MD Randy Grigg, MD Kenneth Kohagen, MD David Konanc, MD Sheila Marshall, DO Jennifer Smith, PharmD Michael Spiritos, MD State Health Plan (SHP) Staff David Boerner,

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at our second quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October

More information

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved. Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.

More information

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative

More information

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

The safety and effectiveness of Dupixent in pediatric patients have not been established (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent

More information

Stivarga. Stivarga (regorafenib) Description

Stivarga. Stivarga (regorafenib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.26 Subject: Stivarga Page: 1 of 5 Last Review Date: September 15, 2017 Stivarga Description Stivarga

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy

GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine

More information

AD/HD is a mental disorder, and it often lasts from

AD/HD is a mental disorder, and it often lasts from short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.

More information

2018 Step Therapy FID 18088

2018 Step Therapy FID 18088 2018 Step Therapy FID 18088 Step Therapy ANTIDEPRESSANTS, SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS LEON 2018 Desvenlafaxine Er Fetzima Fetzima Titration Pack Khedezla Paxil SUSP Pristiq Trintellix

More information

ALLERGIC CONJUNCTIVITIS AGENTS

ALLERGIC CONJUNCTIVITIS AGENTS 2018 5 Tier Standard- Keystone First VIP Choice Document: 2018 Step Therapy Formulary ID: 18390 Last Updated: 04/2018 Effective Date: 05-01-2018 ALLERGIC CONJUNCTIVITIS AGENTS epinastine 0.05 % eye drops

More information

MEDICAID BULLETIN. Providers Indicated

MEDICAID BULLETIN. Providers Indicated South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 www.scdhhs.gov November 27, 2013 MB# 13-060 TO: MEDICAID BULLETIN Providers Indicated Phys

More information

Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information

Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD

More information

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication. ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider Bulletin October 2018 Quarterly pharmacy formulary change notice The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. The changes listed in the table

More information

Pharmacy Updates Summary

Pharmacy Updates Summary All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines

More information

BlueLink TPA FlexRx Updates

BlueLink TPA FlexRx Updates BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%

More information

UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting

UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting

More information

TABLE OF CONTENTS (Click on a link below to view the section.)

TABLE OF CONTENTS (Click on a link below to view the section.) Follow the links below to access the complete formularies for Plans: Buckeye Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral

More information

Rayos Prior Authorization Program Summary

Rayos Prior Authorization Program Summary Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive

More information

LIST OF DRUGS DURING 2004

LIST OF DRUGS DURING 2004 LIST OF DRUGS DURING 2004 S.NO Name Of Drug Pharmacological Classification Date of Approval 188 Dutasteride For BPH 16-02-2004 189 Gefitinib Anti-cancer 17-02-2004 190 Imidapril Anti-hypertensive 23-02-2004

More information

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6 in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,

More information

2018 Step Therapy (ST) Criteria

2018 Step Therapy (ST) Criteria 2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance

More information

Your prescription benefit updates Formulary Updates - Effective January 1, 2019

Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Medications are grouped by the conditions they treat. Each medication is placed in a tier that shows the amount you will

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1067-7 Program Prior Authorization/Notification Medication Nexavar (sorafenib tosylate) P&T Approval Date 8/2008, 6/2009, 6/2010,

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Quarterly pharmacy formulary change notice Provider update Summary: The formulary changes listed in the table below were reviewed and approved at our second quarter 2018, Pharmacy and Therapeutics Committee

More information

Medications and Children Disorders

Medications and Children Disorders Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for

More information

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Comparison of representative topical corticosteroid preparations (classified according to the US system) Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),

More information

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your UA Medicare Part D Prescription Drug Plan before filling prescriptions for the drugs shown

More information

Oregon Health Plan prescription benefit updates

Oregon Health Plan prescription benefit updates Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save

More information

DRUG SCHEDULES REGULATION CHANGES JUNE 2018

DRUG SCHEDULES REGULATION CHANGES JUNE 2018 DRUG SCHEDULES REGULATION CHANGES JUNE 2018 The following amendments to the Schedules to the Drug Schedules Regulation made under the Pharmacy Operations and Drug Scheduling Act came into effect on June

More information

Tasigna. Tasigna (nilotinib) Description

Tasigna. Tasigna (nilotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)

More information

Tasigna. Tasigna (nilotinib) Description

Tasigna. Tasigna (nilotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Added, Removed or Changed. Date of Change. No Change

Added, Removed or Changed. Date of Change. No Change One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your

More information

Advantage by Peach State Health Plan 2012 Prior Authorization Listing. Approved 10/23/2011 Effective October 2011

Advantage by Peach State Health Plan 2012 Prior Authorization Listing. Approved 10/23/2011 Effective October 2011 Advantage by Peach State Health Plan 2012 Approved 10/23/2011 Effective October 2011 Note to members: The prior authorization requirements are listed to provide you with information to discuss treatment

More information

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code

More information

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee

More information

Conversion from focalin xr to vyvanse

Conversion from focalin xr to vyvanse Conversion from focalin xr to vyvanse The Borg System is 100 % Conversion from focalin xr to vyvanse Sep 3, 2007. The importance of the 'conversion' dosing listed above relates to those people who may

More information

Pharmacologic Treatment of Atopic Dermatitis

Pharmacologic Treatment of Atopic Dermatitis J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc

More information

MDwise Self-Administered Codes for Medical

MDwise Self-Administered Codes for Medical The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively

More information